PROCEPT BioRobotics PRCT 深 沪
已收盘 10-09 16:00:00 美东时间
18.40
+0.500
+2.79%
华盛通- 最 高18.44
- 今 开17.78
- 成交量 111.41万股
- 最 低 17.78
- 昨 收 17.90
- 总市值 10.54亿
- 52周最高 38.11
- 市盈率 静 --
- 换手率 1.95%
- 52周最低 16.665
- 委 比 -99.16%
- 总股本 5727.37万
- 历史最高 103.8099
- 量 比 1.01
- 振 幅 3.69%
- 历史最低 15.38
- 每 手 1
- 风险率 5.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30
Barclays analyst Christopher Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight rating and announces Price Target of $30.
10-07 21:05
PROCEPT BioRobotics Adds Esteemed Surgeon to Board
PROCEPT BioRobotics ( ($PRCT) ) has issued an announcement. On October 2, 2026,...
10-03 05:19
PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
PROCEPT BioRobotics Corporation will present at the Baird 2026 Global Healthcare Conference in New York City on September 15. The company, focused on advancing urology care, manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system delivering AI-powered Aquablation therapy for BPH-related LUTS. The therapy aims to provide effective outcomes regardless of prostate size or surgeon experience. PROCEPT also pursues clinical resea...
08-17 12:00
财报速睇 | PROCEPT BioRobotics 2026财年Q2营收0.94亿美元，同比增长19.4%；归母净利润亏损0.27亿美元，同比亏损扩大37.2%
华盛资讯8月6日讯，PROCEPT BioRobotics公布2026财年Q2业绩，公司Q2营收0.94亿美元，同比增长19.4%，归母净利润亏损0.27亿美元，同比亏损扩大37.2%。
08-06 09:10
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
PROCEPT gains after Q2 beat; Wells Fargo downgrades
Shares of PROCEPT BioRobotics (PRCT) gained on Wednesday after the surgical robotics company exceeded Street forecasts with its Q2 2026 revenue, even as Wells Fargo downgraded it, citing an abrupt sof...
08-06 01:38
Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23
Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.
08-05 22:22
William Blair Downgrades PROCEPT BioRobotics to Market Perform
William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
08-05 18:55
财报速睇 | PROCEPT BioRobotics 2026财年Q2营收0.94亿美元，同比增长19.3%；归母净利润亏损0.27亿美元，同比亏损扩大37.2%
华盛资讯8月5日讯，PROCEPT BioRobotics公布2026财年Q2业绩，公司Q2营收0.94亿美元，同比增长19.3%，归母净利润亏损0.27亿美元，同比亏损扩大37.2%。
08-05 06:35
